Treating Community-Acquired Bacterial Pneumonia (CABP): A Systemic Pleuromutilin Antibacterial in the Outpatient Setting
Industry Webcast Sponsored by Nabriva Therapeutics US, Inc.; Not for CME/CE Credit
Antimicrobial resistance, especially pneumococcal resistance to macrolide antibiotics, or potential safety concerns of commonly used antibiotics result in underserving certain patients with CABP. A systemic pleuromutilin antibacterial may be a treatment alternative for these underserved patients.
This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.